Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Eli Lilly’s Acute Migraine Treatment Meets Goal in Phase III Study

By Ryan Bushey | August 4, 2017

Another promising drug for migraines is moving closer to approval.

Eli Lilly reported lasmiditan, an investigational oral first-in-class molecule for the acute treatment of migraines, achieved dosing goals in a second Phase III study called SPARTAN.

SPARTAN is a randomized, double, placebo-controlled trial assessing the safety and efficacy of three different doses of lasmiditan on patients who experienced at least moderate migraine disability. Most participants had an average of more than five migraine attacks per month at baseline.

Investigators tested the impact of 50 mg, 100 mg, or 200 mg against placebo on these patients.

The primary endpoint was reached when the percentage of patients who were migraine pain-free was statistically significantly greater compared to placebo in all dosing groups. It broke down to 28.6 percent for the 50 mg cohort, 31.4 percent for the 100 mg group and 38.8 percent for 200 mg compared 2.13 percent for placebo.

Furthermore, key secondary endpoints when a statistically significant greater percentage of patients were free of their most bothersome symptoms like nausea and sensitivity to sound versus placebo were met two hours following the first dose, according to the announcement. 

“Lasmiditan represents the first significant innovation in the acute treatment of migraine in more than 20 years, and could provide a much-needed new treatment option for the 36 million Americans living with migraine,” said Lilly Bio-Medicines president Christi Shaw, in a statement. “We are thrilled with these topline lasmiditan results, which add to more than 25 years of Lilly’s research and development of migraine therapies.”

Common adverse events that were reported included dizziness, paresthesia, and somnolence.

More detailed data from this study as well another investigation labeled SAMURAI will be presented at upcoming scientific meetings while the SPARTAN results will be submitted to peer-reviewed journals within the next year.

Also, Eli Lilly plans on submitting a New Drug Application to the U.S. Food and Drug Administration in the second half of 2018.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE